Locust Walk is partnering with Applied Molecular Transport, Forma Therapeutics, and Goodwin for a live panel on Thursday, July 23rd from 1-2 pm EST entitled “The Unexpected IPO Boom for Biopharma in Q2.”
Q2 saw a boom in IPOs, while many biopharma companies continue to seek capital in both public and private markets, including multiple crossover rounds — a key factor that has helped the industry ride through the COVID-19 market disclocations. For additional insight, please see Locust Walk’s Q2 2020 Report: Global Trends in Biopharma Transactions.
Seo Salimi also contributed to a Goodwin thought piece entitled “Capital Markets in the Time of Pandemic – Second Quarter Biotech Update,” and he will also be sharing his capital markets perspective and insight.
To further discuss the positive industry perception, we are proud to partner with Applied Molecular Transport, a clinical-stage biopharma company developing novel oral biologics to treat autoimmune, inflammatory, metabolic, and other diseases. In June of this year, they announced the closing of its IPO.
In addition, Forma Therapeutics, a clinical-stage biopharma company focused on rare hematologic diseases and cancers, also announced the closing of its IPO in June.
In this panel, we’ll dive into and discuss:
- Planning process for their IPOs this year
- How their crossover rounds impacted their IPO
- The experience of a virtual roadshow
- What’s next?
Geoff Meyerson, Moderator, CEO & Co-Founder, Locust Walk
Liz Bhatt, CBO, Applied Molecular Transport
Shawn Cross, CFO, Applied Molecular Transport
Seo Salimi, Partner, Life Sciences Capital Markets Group, Goodwin
Todd Shegog, CFO, Forma Therapeutics